# Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

> **NCT04809181** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 95 (estimated)

## Conditions studied

- Hematologic Malignancy
- Stem Cell Transplant Complications

## Interventions

- **DRUG:** Azacitidine in Combination With Venetoclax

## Key facts

- **NCT ID:** NCT04809181
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-19
- **Primary completion:** 2024-03-19
- **Final completion:** 2026-03-19
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809181, "Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04809181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*